Dr. Dushyant Varshney is a seasoned biopharmaceutical executive, board member and strategic advisor with over 25 years of global leadership in advancing companies with innovative therapies (40+ product launches) including RNA medicines (first self-amplifying mRNA COVID-19 vaccine Kostaive® approved in Japan), cell & gene products (YESCARTA® and TECARTUS®), immuno-oncology, biologics, vaccines, radiopharmaceuticals and sterile injectables. Dr. Varshney has held C-suite, executive and leadership roles at Arcturus Therapeutics, Gilead-Kite Pharma, Pfizer, Novartis, Jubilant, Sanofi and Bristol-Myers Squibb and Lilly.

Dr. Varshney has led C-suite teams and Board of directors for start-up and early-stage companies, and contributed to multiple licensing, 20+ M&A deals and fund-raising for clinical and commercial assets.  At SlingstoneBio, Dr. Varshney serves as the Chairman of the Board, guiding the company’s strategic business growth to advance pre-clinical immuno-oncology pipeline.